Bioventix plc
(“Bioventix” or the “Company”)
Unaudited Interim Results for the six months ended 31 December 2018
Bioventix plc (BVXP) (“Bioventix” or “the Company”), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its unaudited interim financial results for the six-month period ended 31 December 2018.
To download this report as a PDF file click here.
Unaudited interim results for the six months ended 31st December 2018.
TR-1: Notification of major interest in shares.
To download this report as a PDF file click here.